Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Fetal Embolization for Severe Vein of Galen Malformation - A Feasibility and Safety Trial

4 novembre 2026 aggiornato da: Michael A Belfort

Fetal Embolization Via Transcardiac Transarterial Ultrasound and Fluoroscopy-guided Endovascular Surgery (FETTUS) for Severe Vein of Galen Malformation - A Feasibility and Safety Trial

The goal of this clinical trial is to evaluate the feasibility and safety of fetal embolization for severe, otherwise lethal, Vein of Galen Malformation (VOGM) via a laparotomy-assisted approach by assessing maternal, fetal, neonatal, and infant outcomes in a cohort of 10 participants. The hypothesis is that in utero embolization of severe VOGM will reduce postnatal mortality and morbidity in severe VOGM infants with minimal maternal risks and acceptably low fetal risks.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Participants will be offered the FETTUS technique as an alternative to the traditional standard postnatal VOGM embolization if all study criteria are met. During the surgery, the mother's uterus is exteriorized using the standard laparotomy approach that we currently use for our fetoscopic spina bifida repair and then transuterine fetal cardiac access is obtained under continuous ultrasound guidance. Once the needle is in place, a microcatheter is advanced through the blood vessels in the heart and up to the site of the malformation in the brain. The malformation will be embolized using medical-grade glue (Trufill n-BCA Liquid Embolic System, Johnson & Johnson)

All participants will be closely followed with postoperative ultrasound scans and consultations. Delivery will be scheduled at Texas Children's Hospital, and the infants will be followed by our research team until they reach 24 months of age.

Tipo di studio

Interventistico

Iscrizione (Stimato)

10

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

  • Stati Uniti
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Texas Children's Hospital
        • Sub-investigatore:
          • William Whitehead, MD, MPH
        • Sub-investigatore:
          • Luc Joyeux, MD, PhD
        • Sub-investigatore:
          • Magdalena Sanz Cortes, MD, PhD
        • Sub-investigatore:
          • Caitlin Sutton, MD
        • Contatto:
          • Becky Johnson, MS
          • Numero di telefono: 832-826-7451
          • Email: rj2@bcm.edu
        • Contatto:
          • Michael Belfort, MD, PhD
          • Numero di telefono: 832-826-7375
          • Email: belfort@bcm.edu
        • Sub-investigatore:
          • Becky Johnson, MS, CCRP
        • Investigatore principale:
          • Michael Belfort, MD, PhD
        • Sub-investigatore:
          • Karen Chen, MD
        • Sub-investigatore:
          • Carolyn Altman, MD
        • Sub-investigatore:
          • Jessian Munoz, MD, PhD, MPH
        • Sub-investigatore:
          • Samuel McClugage, MD
        • Sub-investigatore:
          • Howard Weiner, MD
        • Sub-investigatore:
          • Dajana Sabic, DO
        • Sub-investigatore:
          • Lisa Emrick, MD
        • Sub-investigatore:
          • Larry Hollier, MD
        • Sub-investigatore:
          • Thierry Huisman, MD, PhD
        • Sub-investigatore:
          • David Mann, MD, DBe

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  1. Pregnant woman - maternal age 18 years or older

  2. Singleton pregnancy

  3. Prenatal sonographic evidence of Vein of Galen Malformation (VOGM) between 23-0/7 and 37-0/7 weeks of gestation

  4. VOGM volume ratio (VBR) >9.69% and narrowest mediolateral diameter of the straight or falcine sinus (>10.15 mm) on prenatal magnetic resonance imaging (MRI)

  5. Worsening VOGM severity on follow up prenatal imaging (i.e. ultrasound, MRI and/or echocardiography), and exceeding the specified threshold measurements in any one or more of the following prognostic markers: VOGM varix volume (≥10.9cm3), new or progressive middle cerebral artery pseudofeeders, and/or worsening combined cardiac index (CCI >750 mL/kg/min).

  6. Absence of bilateral extensive brain damage on fetal MRI

  7. Absence of significant* fetal anomalies unrelated to VOGM on fetal US and/or MRI imaging

  8. Gestational age at the time of the procedure will be between 30-0/7 and 37-0/7 weeks

  9. Negative maternal serological tests for HIV, Hepatitis B and Hepatitis C because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the pregnant woman's HIV status or Hepatitis status is unknown, she must be tested and found to have negative results before enrollment

  10. The pregnant woman has considered and declined termination of pregnancy

  11. The pregnant woman meets psychosocial criteria (sufficient social support, ability to understand the requirements of the study)

  12. Signed informed consent by participant and the father of the baby

    • Significant associated anomalies are defined as such anomalies that would, in and of themselves, be life limiting or life threatening. A minor anomaly, such as a small VSD or ASD not deemed to be life limiting or threatening, or a cleft lip or other such anomaly, unless part of a genetic syndrome, will not disqualify the fetus.

Exclusion Criteria:

  1. Extensive fetal brain parenchymal injury or gliosis on fetal MRI, defined as greater than one quarter of supratentorial brain volume consistent with advanced irreversible brain injury
  2. Severe hydrops fetalis on fetal ultrasound, characterized by large-volume effusions resulting in organ compression, diffuse fetal skin edema, and marked cardiomegaly
  3. Increased risk for preterm labor including short cervical length (≤ 2.0 cm), history of incompetent cervix with or without cerclage, and previous preterm birth in a singleton pregnancy (other than a patient delivered for a non-repeating medical or surgical indication)
  4. Placental abnormalities (previa, abruption, accreta) known at time of enrollment
  5. Pre-pregnancy body-mass index (BMI) ≥40
  6. Contraindications to surgery including previous hysterotomy (whether from a previous classical cesarean, uterine anomaly such as an arcuate or bicornuate uterus, major myomectomy resection, or previous fetal surgery) in active uterine segment
  7. Technical limitations precluding fetal surgery, such as extensive uterine fibroids, fetal membrane separation, or uterine anomalies
  8. Maternal-fetal Rh alloimmunization, Kell sensitization, or neonatal alloimmune thrombocytopenia affecting the current pregnancy
  9. Maternal medical condition that is a contraindication to surgery or anesthesia, i.e. any inadequately controlled maternal medical condition resulting in an American Society of Anesthesiologists (ASA) Physical Status classification of III or higher
  10. Low amniotic fluid volume (Amniotic Fluid Index less than 5cm), unresponsive to maternal hydration, if deemed to be due to fetal anomaly, poor placental perfusion or function, or membrane rupture
  11. The pregnant woman does not have a support person (i.e., spouse, partner, family member, or close friend) available to support her for the duration of the pregnancy
  12. Inability to comply with the travel and follow-up requirements of the trial
  13. The pregnant woman has severe depression and has not been cleared by a psychiatrist
  14. The pregnant woman is enrolled or has been enrolled in any another intervention study that affects the mother or fetus
  15. Maternal contraindications to nonionic contrast agent such as acute thyroid dysfunction and acute kidney injury
  16. Maternal hypersensitivity to any of the entities associated with the use of nonionic contrast agent. The use of Omnipaque distributed by GE Healthcare company is contraindicated for participants sensitive to any of the components listed on the container package, i.e. Iohexol (Bis(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)-acetamido]-2,4,6-triiodoisophthalamide), edetate calcium disodium and tromethamine
  17. Maternal hypersensitivity to any of the entities associated with the use of liquid embolic system. The use of Trufill (n-BCA) distributed by Cerenovus - Johnson&Johnson company is contraindicated for participants sensitive to any of the components listed on the container, i.e. n-BCA, Ethiodized Oil and Tantalum Powder

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Fetal Embolization

This is a single arm study in which participants will undergo a one-time intervention of fetal embolization for severe Vein of Galen Malformation.
Prodotto combinato: Fetal embolization of severe Vein of Galen Malformation using a liquid embolic system

Participants will undergo a laparotomy, exteriorization of the uterus, and uterine needle puncture to obtain fetal cardiac access so a catheter can be inserted into an artery and guided up to the site of the malformation. A liquid embolic system (Trufill n-Butyl CyanoAcrylate, Johnson & Johnson) will be used to occlude the dominant arterial pedicle supplying the shunt.

Altri nomi:
  • FETTUS

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: From the date of fetal embolization until the date of discharge from the NICU, or the date of death from any cause, whichever came first, assessed up to 24 months

If the fetal survives to delivery and discharge from the neonatal intensive care unit (NICU)
From the date of fetal embolization until the date of discharge from the NICU, or the date of death from any cause, whichever came first, assessed up to 24 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Feasibility of FETTUS in Cases of Severe Vein of Galen Malformation
Lasso di tempo: At the end of the fetal embolization procedure

If all of the following occurs:

  1. There is successful embolization of the target feeding artery
  2. The fetus survives through the end of the embolization procedure
At the end of the fetal embolization procedure
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: At the end of the fetal embolization procedure

Fetal and infant morbidity and mortality will be assessed using the following outcomes:

  1. Fetal Demise
  2. Fetal bradycardia/arrhythmia
  3. Hydrops fetalis
  4. Fetal intracranial hemorrhage
  5. Emergent delivery
At the end of the fetal embolization procedure
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: At the end of the fetal embolization procedure

Fetal and infant morbidity and mortality will be assessed using the following outcomes:

  1. Contrast agent (cumulative contrast dose)
  2. Cumulative radiation dose
At the end of the fetal embolization procedure
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: From date of fetal embolization to date of maternal discharge after the in-utero procedure, assessed up to 4 weeks

Fetal and infant morbidity and mortality will be assessed using the following outcomes:

  1. Fetal demise
  2. Fetal intracranial hemorrhage
  3. Need for emergent delivery
From date of fetal embolization to date of maternal discharge after the in-utero procedure, assessed up to 4 weeks
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: From date of fetal embolization to date of maternal discharge after the in-utero procedure, assessed up to 4 weeks

Fetal and infant morbidity and mortality will be assessed using the following outcomes:

Maternal length of stay (in days)
From date of fetal embolization to date of maternal discharge after the in-utero procedure, assessed up to 4 weeks
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: From date of fetal embolization to date of delivery, assessed up to 10 weeks

Fetal and infant morbidity and mortality will be assessed using the following outcomes:

  1. Intrauterine growth restriction (IUGR)
  2. Intrauterine fetal demise (IUFD)
From date of fetal embolization to date of delivery, assessed up to 10 weeks
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: From date of fetal embolization to date of delivery, assessed up to 10 weeks

Fetal and infant morbidity and mortality will be assessed using the following outcomes:

Gestational age at delivery
From date of fetal embolization to date of delivery, assessed up to 10 weeks
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: From date of fetal embolization to date of delivery, assessed up to 10 weeks

Fetal and infant morbidity and mortality will be assessed using the following outcomes:

Birth weight (grams)
From date of fetal embolization to date of delivery, assessed up to 10 weeks
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: From date of fetal embolization to date of delivery, assessed up to 10 weeks

Fetal and infant morbidity and mortality will be assessed using the following outcomes:

  1. Bicêtre VOGM prognosis score (0-21)
  2. APGAR scores
  3. Number of events related to glue migration
From date of fetal embolization to date of delivery, assessed up to 10 weeks
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: From date of fetal embolization to date of delivery, assessed up to 10 weeks

Fetal and infant morbidity and mortality will be assessed using the following outcomes:

Umbilical artery pH
From date of fetal embolization to date of delivery, assessed up to 10 weeks
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: At hospital discharge or date of death, whichever came first, assessed up to 24 months

Fetal and infant morbidity and mortality will be assessed using the following outcomes:

  1. Neonatal or infant death
  2. Cardiac arrhythmia and/or reduced ejection fraction on echocardiography
  3. Focal neurological deficit
  4. Seizure
  5. Stroke (hemorrhagic vs. focal non-hemorrhagic)
  6. Global cortical atrophy or gliosis
  7. Delayed myelination
  8. Arteriovenous shunting
  9. Liver failure
  10. Renal failure
  11. Thyroid dysfunction
  12. Complications related to prematurity
At hospital discharge or date of death, whichever came first, assessed up to 24 months
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: At hospital discharge or date of death, whichever came first, assessed up to 24 months

Fetal and infant morbidity and mortality will be assessed using the following outcomes:

Number of events related to glue migration
At hospital discharge or date of death, whichever came first, assessed up to 24 months
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: At hospital discharge or date of death, whichever came first, assessed up to 24 months

Fetal and infant morbidity and mortality will be assessed using the following outcomes:

  1. Duration of intubation (days)
  2. Time on pressors (in days)
  3. Time on treatment for pulmonary hypertension (in days)
  4. Time to initiation of enteral feeds (in days)
  5. Time on total parenteral nutrition (TPN) (in days)
  6. Length of hospital stay (in days)
At hospital discharge or date of death, whichever came first, assessed up to 24 months
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: At 12 and 24 months of age

Fetal and infant morbidity and mortality will be assessed using the following outcomes:

  1. Infant Death
  2. Need for additional embolizations
  3. Renal failure
  4. Thyroid dysfunction
  5. Stroke (hemorrhagic vs. focal non-hemorrhagic)
  6. Global cortical atrophy or gliosis
  7. Delayed myelination
  8. Arteriovenous shunting
  9. Hydrocephalus
  10. Focal neurological deficit
  11. Seizure
At 12 and 24 months of age
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: At 12 and 24 months of age

Fetal and infant morbidity and mortality will be assessed using the following outcomes:

Neurodevelopmental outcomes (Developmental Profile Assessment, Capute Scales, Revised Gesell Developmental Schedules)
At 12 and 24 months of age
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: From date of fetal embolization to date of delivery, assessed up to 10 weeks

Maternal morbidity and mortality will be assessed using the following outcomes:

  1. Mortality
  2. Contrast-agent-related complications
  3. Anesthesia complications
  4. Pulmonary edema
  5. Need for blood transfusion
  6. Wound infection.
  7. Chorioamniotic membrane separation
  8. Chorioamnionitis
  9. Oligohydramnios
  10. Preterm labor
  11. Preterm delivery
  12. Preterm premature rupture of membranes
  13. Placental abruption
  14. Maternal postoperative readmission for a procedure-related complication
From date of fetal embolization to date of delivery, assessed up to 10 weeks
Safety of FETTUS in Cases of Severe Vein of Galen Malformations
Lasso di tempo: From date of fetal embolization to date of delivery, assessed up to 10 weeks

Maternal morbidity and mortality will be assessed using the following outcomes:

Number of events related to glue migration
From date of fetal embolization to date of delivery, assessed up to 10 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Michael A Belfort

Collaboratori

Baylor College of Medicine

Investigatori

  • Investigatore principale: Michael Belfort, MD, PhD, Baylor College of Medicine and Texas Children's Hospital
  • Direttore dello studio: Luc Joyeux, MD, PhD, Baylor College of Medicine and Texas Children's Hospital
  • Direttore dello studio: Karen Chen, MD, Baylor College of Medicine and Texas Children's Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 marzo 2027

Completamento primario (Stimato)

1 dicembre 2032

Completamento dello studio (Stimato)

1 dicembre 2035

Date di iscrizione allo studio

Primo inviato

12 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

4 novembre 2026

Primo Inserito (Effettivo)

10 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 novembre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • H-57171

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi